| scholarly article | Q13442814 |
| P2093 | author name string | K Tachibana | |
| Y Inoue | |||
| Y Kimura | |||
| H Hidaka | |||
| T Sudo | |||
| K Toga | |||
| S Tochizawa | |||
| P2860 | cites work | Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase | Q22003990 |
| Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A) | Q22010013 | ||
| Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase | Q24322795 | ||
| Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants | Q24323729 | ||
| Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3) | Q28115585 | ||
| Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets | Q28118508 | ||
| Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases | Q28512548 | ||
| Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons | Q28579246 | ||
| Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms | Q29619683 | ||
| Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase | Q31160450 | ||
| Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes | Q34290090 | ||
| Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells | Q36813515 | ||
| Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes | Q37166959 | ||
| A novel insulin secretagogue is a phosphodiesterase inhibitor | Q38300432 | ||
| Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase | Q39983359 | ||
| Cyclic nucleotide phosphodiesterases and vascular smooth muscle | Q41048208 | ||
| Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation | Q41786301 | ||
| The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors | Q41929087 | ||
| Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity | Q42036761 | ||
| Regulation of calcyclin (S100A6) binding by alternative splicing in the N-terminal regulatory domain of annexin XI isoforms | Q42060884 | ||
| Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms | Q42238781 | ||
| Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors | Q43475071 | ||
| Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle | Q69834771 | ||
| Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021 | Q70868716 | ||
| Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities | Q71516589 | ||
| Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography | Q72400640 | ||
| Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury | Q73486413 | ||
| 2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities | Q77748844 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 347-56 | |
| P577 | publication date | 2000-02-15 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity | |
| P478 | volume | 59 |
| Q34953389 | Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4. |
| Q34171317 | Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice |
| Q89220120 | Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose |
| Q37269861 | Antithrombotic agents for stroke prevention |
| Q37046760 | Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. |
| Q54976758 | Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4. |
| Q39072124 | Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease? |
| Q26781612 | Cardiac cAMP: production, hydrolysis, modulation and detection |
| Q44506538 | Characterization of platelet aggregation in whole blood of laboratory animals by a screen filtration pressure method |
| Q28546598 | Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells |
| Q42910105 | Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial |
| Q34540133 | Cilostazol improves symptomatic intracranial artery stenosis - Evaluation of cerebral blood flow with single photon emission computed tomography |
| Q28213018 | Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation |
| Q39229705 | Cilostazol strengthens barrier integrity in brain endothelial cells |
| Q33509456 | Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes |
| Q37657841 | Clinical and molecular genetics of the phosphodiesterases (PDEs). |
| Q34559471 | Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures |
| Q28740548 | Cyclic AMP control measured in two compartments in HEK293 cells: phosphodiesterase K(M) is more important than phosphodiesterase localization |
| Q40771287 | Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility |
| Q38052592 | Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters. |
| Q44345043 | Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives as inotropic agents |
| Q34192834 | Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes |
| Q41865256 | Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes. |
| Q38187182 | Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. |
| Q37332621 | Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease |
| Q33874668 | Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study |
| Q45954508 | Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. |
| Q92312512 | Efficacy of dual antiplatelet therapy as premedication before diagnostic cerebral digital subtraction angiography |
| Q28579775 | Elevation of intracellular cAMP up-regulated thrombomodulin mRNA in cultured vascular endothelial cells derived from spontaneous type-II diabetes mellitus model rat |
| Q93551725 | Enzymes |
| Q64243483 | Essential Roles for the Non-Canonical IκB Kinases in Linking Inflammation to Cancer, Obesity, and Diabetes |
| Q28187885 | Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method |
| Q37408180 | Evaluation and Treatment of the Acute Cerebral Infarction with Convexal Subarachnoid Hemorrhage |
| Q41256836 | Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells |
| Q28212847 | Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens |
| Q47316523 | Hypothalamic Phosphodiesterase 3B Pathway Mediates Anorectic and Body Weight-Reducing Effects of Insulin in Male Mice. |
| Q46423033 | Increased particulate phosphodiesterase 4 in the prefrontal cortex supports 5-HT4 receptor-induced improvement of object recognition memory in the rat. |
| Q42089521 | Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. |
| Q28484521 | K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model |
| Q28477308 | Neurite outgrowth mediated by translation elongation factor eEF1A1: a target for antiplatelet agent cilostazol |
| Q41506768 | Novel cilostamide analogs, phosphodiesterase 3 inhibitors, produce positive inotropic but differential lusitropic and chronotropic effects on isolated rat atria |
| Q42419157 | Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility |
| Q57476483 | PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment |
| Q48582088 | Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase |
| Q38738498 | Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle |
| Q41718404 | Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties. |
| Q42458734 | Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats. |
| Q93498588 | Phosphodiesterases, 3′,5′-cyclic nucleotide (E.C.3.1.4.17) |
| Q44645429 | Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets |
| Q33552229 | Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts |
| Q37686116 | Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP. |
| Q36159287 | Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension |
| Q49630261 | Protective effects of cilostazol on ethanol-induced damage in primary cultured hepatocytes |
| Q34231776 | Role of Ser102 and Ser104 as regulators of cGMP hydrolysis by PDE5A |
| Q41939506 | Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model |
| Q92489038 | Synergic PDE3 and PDE4 control intracellular cAMP and cardiac excitation-contraction coupling in a porcine model |
| Q48254467 | Synergy between 5-HT4 receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle |
| Q38205932 | Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases. |
| Q30486745 | The Concise Guide to PHARMACOLOGY 2013/14: enzymes. |
| Q34995043 | The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population--an updated meta-analysis |
| Q53515405 | The headache-inducing effect of cilostazol in human volunteers. |
| Q46298247 | WITHDRAWN: Effect of cilostazol in alleviating cardiovascular complications through regulation of type 1 plasminogen activator inhibitor and transforming growth factor-β1 overexpression in experimental rats |
| Q55257365 | cAMP Catalyzing Phosphodiesterases Control Cholinergic Muscular Activity But Their Inhibition Does Not Enhance 5-HT4 Receptor-Mediated Facilitation of Cholinergic Contractions in the Murine Gastrointestinal Tract. |
| Q34456605 | β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells |
Search more.